Brief: Anixa Biosciences Completes Treatment Of First Patient Cohort In Ovarian Cancer CAR-T Clinical Trial
13/10/2023 13:33
Oct 13 (Reuters) - Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES COMPLETES TREATMENT OF FIRST PATIENT
COHORT IN
OVARIAN CANCER CAR-T CLINICAL TRIAL
* ANIXA BIOSCIENCES INC - WITH NO DOSE-LIMITING TOXICITIES
OBSERVED, TREATMENT OF SECOND DOSE COHORT TO BEGIN
Source text for Eikon: ID:nPn8qxNw6a
Further company coverage: ANIX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine